July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug ...

MEXICO: TANZANIA is pursuing a comprehensive strategy to tackle malnutrition while addressing the growing burden of ...

Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic ...

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising ...

A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International ...

A review suggests that although obesity medications, such as GLP-1 drugs, can result in substantial weight loss, many obesity ...

Novo Nordisk said about two in three people in India have fatty liver disease, which offers immense potential for the ...

A decade ago, in March 2016, Prime Minister Narendra Modi first mentioned obesity in his 18th Mann Ki Baat address. Since ...

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development ...

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic ...

The 2026 American Fitness Index ranks cities based on the health of individuals, community and environment. How did St. Louis ...

Share on Pinterest Eating an avocado a day may reduce the risk of heart disease in adults with obesity. Image credit: Getty Images / WhiteTea A study suggests that eating 1 avocado per day can reduce ...